Abstract
We investigated the association between an increased intake of one dairy product subgroup at the expense of another within a 5-year period and the subsequent 10-year risk of developing type 2 diabetes. Effect modification by the initial level of the dairy product intake was also examined. The cohort included 39,438 men and women with two measurements of diet assessed using food frequency questionnaires (FFQ) administered in 1993-1997 and 1999-2003. Dairy products were skimmed milk, semi-skimmed milk, whole-fat milk, buttermilk, low-fat yogurt, whole-fat yogurt, cheese and butter. Type 2 diabetes cases were ascertained from the Danish National Diabetes Register. The pseudo-observation method was used to calculate risk differences (RD) with 95% confidence intervals (CI). Among participants aged 56-59 years at hand-in of the follow-up FFQ, increased intake of whole-fat yogurt in place of skimmed, semi-skimmed or whole-fat milk was associated with a reduced risk (RD% [95% CI]: −0.8% [−1.3, −0.2]; −0.6% [−1,1, −0.1]; −0.7 [−1.2, −0.1]; per 50g/d, respectively). Among participants aged 60-64 and 65-72, substitution of skimmed milk for semi-skimmed milk was associated with an increased risk of type 2 diabetes (0.5% [0.2, 0.7]; 0.4% [0.1, 0.7]; per 50g/d, respectively). No effect modification by the initial intake of milk products was observed. Our results suggest that substitution of whole-fat yogurt for milk among those aged 56-59 decreases the risk of type 2 diabetes and substitution of skimmed milk for semi-skimmed milk was associated with an increased risk of type 2 diabetes among those aged 60-64 and 65-72, regardless of the initial intake level.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Daniel B. Ibsen was supported by a PhD fellowship by Aarhus University and Tuomas O. Kilpelainen was supported by the Novo Nordisk Foundation (NNF18CC0034900 and NFF17OC0026848). The Diet, Cancer and Health cohort was funded by Danish Cancer Society. The funding agencies had no influence on the design, analysis or writing of this paper.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Regional Ethical Committees on human studies and by the Danish Data Protection Agency.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data described in this article may be made available upon request pending on application to and approval by the Danish Cancer Society(e-mail: dchdata{at}cancer.dk).
Abbreviations
- BMI
- Body mass index
- CI
- Confidence interval
- FFQ
- Food frequency questionnaire
- RD
- Risk difference
